3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
15
Observational
1
Expanded_access
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Recurrence
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Stomach Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Appendiceal Neoplasms
1
Interventions
atezolizumab
5
avelumab
4
erdafitinib
1
enfortumab vedotin
1
darolutamide
1
Therapeutics
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Radiotherapy
1
Patient Reported Outcome Measures
1
Nivolumab
1
Mitomycin
1
Magnetic Resonance Spectroscopy
1
Laparoscopy
1
Immunotherapy
1
Histocompatibility Testing
1
High-Throughput Nucleotide Sequencing
1
Hematologic Tests
1
Gemcitabine
1
Focus Groups
1
Educational Status
1
Drug Therapy
1
Defecation
1
Cytological Techniques
1
Cystoscopy
1
Cisplatin
1
Carboxylesterase
1
Blood Cell Count
1
Biomarkers
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Carcinoma, Transitional Cell
×
Mitomycin
×
Clear all
NCT05874921
2025-02-28
uTRACT
UroGen Pharma Ltd.
Recruiting
400 enrolled